EGFR and neoplasm: One of the first compounds of this series was [18F]ML04, which although retained selectivity for EGFR in vitro was poorly specific in vivo, with high uptake in EGFR negative tumour models and no decrease in tumour radioactivity upon pre-treatment with a blocking dose of cold ML04 [17].